This looks to be the event for RNVS:
messages.finance.yahoo.com
Renovis Updates Progress of Pivotal SAINT II Trial with NXY-059
Top Line Results Expected during the Fourth Quarter of 2006
SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS), today announced that it expects to report top line results from the pivotal SAINT II trial with NXY-059 in coordination with its exclusive licensee, AstraZeneca AB, during the fourth quarter of 2006.
The SAINT II trial is a double-blind, placebo-controlled phase III study in which patients are randomized to receive NXY-059 or placebo within six hours of acute ischemic stroke. The study is designed to confirm the results of the previously completed phase III pivotal SAINT I trial, which met the primary endpoint of reduced patient disability versus placebo following acute ischemic stroke, as assessed on the Modified Rankin Scale (mRS) (p=0.038). Subject to successful completion of SAINT II, AstraZeneca has previously announced that it intends to submit applications for regulatory approval of NXY-059 in the United States and Europe in the first half of 2007.
"AstraZeneca has reported that it expects to complete enrollment of the SAINT II trial ahead of schedule this month with approximately 3,200 patients from more than 350 centers in 30 countries," said Corey S. Goodman, Ph.D., President and Chief Executive Officer of Renovis. "If the SAINT II data are positive, we believe that NXY-059 could fundamentally change the standard of care of acute ischemic stroke patients by allowing treatment of a broad population of patients in a wide array of clinical settings."
NXY-059 is a free radical trapping neuroprotectant and the first compound that has been publicly recognized by the Stroke Treatment Academic Industry Roundtable (STAIR Group) of academic and industry experts to meet their criteria for development of neuroprotective |
